Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Nintedanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 28 Mar 2019 Results evaluating single-agent nintedanib in participants with bevacizumab-resistant recurrent or persistent ovarian, peritoneal, and tubal cancer published in the Gynecologic Oncology
- 13 Oct 2018 Status changed from active, no longer recruiting to completed.
- 12 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Feb 2018.